The Daily Toke

March 31, 2026

# THC & Politics: State-by-State Shifts Signal Major Changes Ahead

Lawmakers across the country are charting divergent paths on cannabis and psychedelics, revealing a fractured political landscape where medical access, gun rights, and public health collide. New Hampshire's House passed a scaled-back psilocybin bill this week that establishes an advisory board to study therapeutic pathways—a significant retreat from the original measure that would have created immediate patient access through regulated programs. The reframing tells a story: even in states moving toward psychedelic medicine, the political will for bold action is narrowing. Simultaneously, the House rejected a separate effort to protect gun rights for registered medical marijuana patients, with lawmakers voting 81-270 to table the measure. The rejection underscores a strange tension in cannabis politics: some states expand medical access while simultaneously imposing collateral restrictions on basic rights tied to that same legal status.

Meanwhile, Georgia is positioning itself as a leader in pragmatic cannabis policy, advancing proposals to ban synthetic hemp products while expanding medical cannabis eligibility and lifting THC concentration caps. 💰 MONEY MOVES The state's current medical program has registered approximately 33,000 patients since July—a modest baseline that expansion could dramatically increase, potentially creating significant tax revenue and a larger patient pool. The moves address a real market problem: as federal restrictions on hemp products loom in November, synthetic derivatives have proliferated, creating an unregulated landscape that concerns lawmakers and safety advocates alike. Banning chemically engineered products while expanding access to regulated medical cannabis represents a distinction worth noting—it's not blanket prohibition, but smart market regulation targeting genuinely questionable manufacturing practices.

[THIS COOL] The political conversation is also shifting on the science side. Recent research published in The Lancet and Canadian studies reveal that while cannabis usage has climbed 40 percent since legalization in 2018 and legal revenues are projected to hit $30.5 billion in 2026, public confidence in cannabis as a mental health treatment is actually declining. The research found little evidence supporting cannabis for anxiety, depression, or PTSD—a reality that's grounding the conversation in actual evidence rather than hype. This matters politically because it gives lawmakers and advocates a shared factual foundation. When eight out of ten Americans now live within driving distance of a cannabis dispensary, the policy debate has matured past ideology into questions of regulation, safety, and legitimate therapeutic use.

The data suggests a normalization underway, but not without friction. 🤔 THINK ABOUT IT New Hampshire rejected gun rights protections for medical patients—people legally registered by their state—while Georgia moves to expand who qualifies for medical access. Some states are creating pathways to psilocybin therapy while others hesitate. The pattern isn't left versus right; it's pragmatism versus caution, often within the same legislative chamber on the same day. As 2026 unfolds and midterm strategies take shape, cannabis policy sits at an inflection point: no longer fringe, but not yet settled. The states moving forward are writing the playbook for what normalization actually looks like—messy, inconsistent, but undeniably in motion.

March 31, 2026

Texas' smokable hemp ban officially took effect on March 31, eliminating products that made up roughly half the state's legal hemp market and forcing immediate store closures across the state. The Department of State Health Services' new regulations redefine how THC is calculated—counting THCA as 88% Delta-9 THC rather than measuring only the finished product's Delta-9 content—effectively banning hemp flower, pre-rolled joints, and most vape products while allowing edibles and beverages to remain legal. 💰 MONEY MOVES Licensing fees for retailers jumped from $155 to $5,000 per location and manufacturer fees from $258 to $10,000, putting immediate financial pressure on businesses that were already losing half their inventory overnight. At least one Dallas-Fort Worth CBD shop, CBD Farmhouse, closed its doors entirely rather than adapt to the new structure, while others like Dallas Hemp Co. braced for a 30 percent revenue loss. The fee increases combined with the product ban created what industry leaders openly describe as a de facto prohibition—one that Gov. Greg Abbott achieved through regulatory channels after vetoing an outright legislative ban last summer.

The legal gray area surrounding out-of-state mail orders has created immediate confusion. Texas health officials claim that any hemp product "introduced into commerce in this state," including items shipped directly to consumers' homes, must comply with the new regulations. Yet cannabis attorneys like Susan Hays argue the state's enforcement mechanism is deeply questionable: prosecutors would face significant obstacles criminalizing purchases of federally legal hemp products shipped across state lines, especially given the 2018 Farm Bill's explicit prohibition on states interfering with hemp transportation. Most law enforcement appears reluctant to pursue such cases, and cannabis lawyers predict that out-of-state retailers will have little hesitation fulfilling Texas orders for now-illegal-in-state products.

For chronic pain patients like Amber Campbell, who was paralyzed following surgery and relies on THCA flower to manage daily pain, the ban presents an immediate healthcare crisis. Campbell explicitly stated she doesn't want to turn to opioids—prescription painkillers that kill over 16,000 Americans annually—yet Texas' medical cannabis program remains severely restricted, requiring doctor approval and limiting access to specific conditions like epilepsy or cancer. Her mother, Sandra Campbell, who owns a CBD American Shaman franchise, is now scrambling to stock medical supplements and alternative products to replace the THCA flower and pre-rolls that once drove business. 🤔 THINK ABOUT IT Prescription opioids kill over 16,000 Americans per year; cannabis kills zero. Yet the state is effectively pushing patients away from a zero-death alternative toward heavily restricted medical access or potentially toward substances with documented mortality rates. The regulatory move may inadvertently increase pressure on chronic pain patients to pursue options with measurable, documented harms.

Industry estimates suggest the ban will hand approximately 50 percent of the legal market to illicit operators, according to Heather Fazio, director of the Texas Cannabis Policy Center. That outcome directly contradicts the stated safety rationale: unregulated products come without testing requirements, child-resistant packaging, or quality standards. The paradox is straightforward—banning regulated, tested hemp products in a state with significant consumer demand doesn't eliminate that demand; it relocates purchases to unregulated channels where products lack the very safety features regulators claim to prioritize. Lukas Gilkey, CEO of Hometown Hero, a major hemp manufacturer, summed up the regulatory approach bluntly: "They did a ban with their own regulatory scheme," noting that the new rules eliminate products "fully legal and fully fine and not harmed anyone."

What happens next depends largely on enforcement and federal law's unclear intersection with state regulation. The 2018 Farm Bill explicitly prevents states from blocking hemp shipments, yet Texas claims authority over in-state retail and online sales. Attorneys expect a slow legal test case, but for now, consumers face an immediate shift: smokable hemp products remain legal to possess, but buying them locally is forbidden, buying them online from in-state retailers is prohibited, and the state officially discourages out-of-state purchases while admitting it may lack practical enforcement tools. The regulatory structure reflects a middle-ground approach—neither full legalization nor criminal prohibition—that satisfies neither industry nor advocates, while pushing medical users and recreational consumers toward gray-market alternatives or away from hemp entirely.

March 31, 2026

Recent research is painting a stark picture of cannabis use that contradicts decades of medical marketing claims—particularly around mental health treatment. A massive meta-analysis published in The Lancet Psychiatry in April 2026, which reviewed 54 clinical trials spanning from 1980 to 2025, found essentially no strong evidence that cannabis helps with anxiety, depression, or PTSD. In fact, researchers flagged potential harms, including increased risk of psychosis and the possibility that cannabis use could delay people from seeking more effective treatment. 🚀 THIS IS COOL The flipside is that CBD-dominant extracts are showing genuine promise for older adults with chronic pain—a new study from the Journal of Pain Research found that full-spectrum CBD extracts outperformed synthetic THC (dronabinol) across every measured category in patients aged 65 and older, with 85.7% meeting the primary effectiveness benchmark compared to just 21.9% in the THC group. The safety profile was also dramatically better, with adverse reactions in 15.5% of CBD users versus 35.7% of THC users.

The mental health findings are particularly important because cannabis use is skyrocketing. According to the latest data, 8 out of 10 Americans now live in a county with at least one cannabis dispensary, and the U.S. legal market is projected to hit $30.5 billion in 2026—a 4% increase from 2025. In Canada, where cannabis has been legal since 2018, usage has jumped 40% since 2017. Yet the research consensus has hardened against using cannabis as a psychiatric treatment. A separate systematic review in JAMA found that nearly a third (29%) of people using cannabis for medical purposes met criteria for cannabis use disorder, and high-potency products were specifically linked to psychotic symptoms. The data here is unambiguous: people are buying cannabis for mental health relief, but the clinical evidence says it doesn't work for that purpose—and might make things worse.

The youth angle is particularly concerning. Research from Harvard and UCLA emphasizes that adolescents and young adults face the highest vulnerability to adverse psychiatric and substance use outcomes from cannabis use. Early, frequent, or high-potency use is linked with worsening anxiety, depression, bipolar disorder, and psychotic illness. One analysis flatly stated: "For teens and young adults, medicinal cannabis has no proven benefits but its use engenders major risks." This is a critical distinction—young people derive essentially zero therapeutic benefit from cannabis while bearing maximum risk. Meanwhile, other research found that cannabis and tobacco use together are linked to reduced brain volumes in specific regions, suggesting structural brain changes that warrant serious attention.

🤔 THINK ABOUT IT There's a curious gap between where the science is pointing and where the regulatory system is moving. Medicare just announced a plan allowing up to $500 annually in hemp-derived cannabinoid products for beneficiaries—a move that sparked federal controversy over whether the Centers for Medicare & Medicaid Services is circumventing FDA drug approval standards. The only FDA-approved cannabis-derived product remains Epidiolex, a pharmaceutical-grade CBD treatment for specific rare epilepsies. About 20% of American adults now use CBD products, yet the clinical evidence supporting most of these uses remains thin. The "entourage effect"—the theory that THC, CBD, and terpenes work synergistically—has partial clinical support but is far from settled science, with several well-designed studies producing contradictory results.

Driving safety is another emerging concern that most casual users probably aren't considering. As medicinal cannabis prescriptions increase, questions about impaired driving are becoming urgent—yet there's no consensus on safe driving windows or standardized roadside testing comparable to alcohol breathalyzers. Meanwhile, cannabis hyperemesis syndrome (severe cyclic vomiting) cases have surged, with vaping accelerating symptom onset. North Carolina just created an Advisory Council on Cannabis to develop a regulatory framework, recognizing that intoxicating THC is already accessible across the state to all ages. The council is studying best practices from other states while trying to balance adult access, youth protection, and public health outcomes.

The bottom line: cannabis is increasingly normalized, increasingly available, and increasingly used for purposes the clinical evidence doesn't support. The real therapeutic signal appears narrowest for specific epilepsy syndromes (where CBD has genuine FDA approval) and possibly for certain chronic pain populations, particularly older adults using CBD-dominant products. For mental health—where marketing and consumer belief are strongest—the evidence has swung sharply toward ineffectiveness and potential harm, especially in younger brains still developing. As policy moves forward, the gap between consumer expectations shaped by marketing and actual clinical evidence remains one of the most significant public health questions in cannabis policy.

March 31, 2026

Texas smokable hemp products became illegal for retail sale on Tuesday as sweeping new regulations from the Department of State Health Services took effect on March 31. The rules cap THC in smokable products at 0.3% by redefining THCA—a compound found in high amounts in hemp flower—as 88% Delta-9 THC. The change effectively eliminates hemp flower, pre-rolled joints, and other inhalable products that industry estimates say represent 25% to 50% of the legal market. While possession of these products remains legal under state law, retailers and manufacturers face a new enforcement regime that prohibits sales.

💰 MONEY MOVES The financial blow to Texas hemp businesses is immediate and severe. Retailer licensing fees jumped from $155 to $5,000 annually per location, while manufacturer fees skyrocketed from $258 to $10,000—increases of roughly 3,200% and 3,800% respectively. One Dallas-area CBD Farmhouse closed entirely rather than comply. Travis Tyler, owner of Smoking Burnouts with six locations, now faces $30,000 in annual permit costs. Kenneth Berner at Burners Vape in the Houston area estimates 90-95% of his revenue depends on smokable hemp products; he expected to lose $10,000 to $15,000 in unsalable inventory even after deep discounting in the final hours before the ban. Store owners spent March 30 in last-minute clearance sales, increasing discounts daily—some offering 10% off each day—just to recoup costs rather than profit.

The regulatory architecture creates enforcement ambiguity that contradicts federal law. State officials at DSHS claim the new rules apply to all products "introduced into commerce in this state," including mail orders from out-of-state companies. But the 2018 Farm Bill explicitly prohibits states from interfering with hemp shipment and transportation. Cannabis attorneys including Susan Hays say prosecuting consumers for purchasing hemp legally shipped from out-of-state jurisdictions remains "doubtful and difficult." Hemp flower remains legal in neighboring New Mexico and Oklahoma. Industry advocates warn the rules will push roughly 50% of the legal market into illicit channels. Heather Fazio, director of the Texas Cannabis Policy Center, stated plainly: "We estimate this will hand 50% of the legal market to illicit operators, making our state less safe."

🤔 THINK ABOUT IT Governor Greg Abbott vetoed an outright ban on all THC hemp products last summer, instead directing state health agencies to regulate the industry. The regulatory path produced stricter child-resistant packaging, testing requirements, and age verification at 21—measures the industry itself largely supports. But the simultaneous product ban combined with 3,000%+ fee increases transforms regulation into de facto prohibition, particularly for smaller independent shops. Cynthia Cabrera, president of the Texas Hemp Business Council, called it "a ban with their own regulatory scheme." Industry leaders argue they weren't given adequate transition time and that the fee structure targets small businesses disproportionately while large operations with capital reserves absorb the costs more easily.

Other product categories survived the March 31 deadline. Hemp-infused edibles, gummies, and beverages remain legal but face new testing, labeling, and child-resistant packaging requirements. THC beverages fall under the Texas Alcoholic Beverage Commission, which has not imposed equivalent restrictions. Vapes were already banned in September 2025. The rules also codify age restrictions to 21 and up, enforce product recall standards, and impose up to $10,000 in daily fines for noncompliance. Hemp industry litigation is already underway; a lawsuit was filed March 17 in Travis County challenging the regulations. Whether those legal challenges succeed, whether out-of-state mail order remains accessible, and whether enforcement will prioritize illicit operators over consumers remains to be determined under the new regulatory regime.